

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

APR 03 2002

TECH CENTER 1600/2900

Inventor Application of:  
Stephen A. Johnston *et al.*

Group Art Unit: 1635

Examiner: Unknown

Atty. Dkt. No.: UTSD:736US/MBW

Serial No.: 10/023,437

Filed: December 17, 2001

For: METHODS AND COMPOSITIONS FOR  
VACCINATION COMPRISING  
NUCLEIC ACID AND/OR  
POLYPEPTIDE SEQUENCES OF  
CHLAMYDIA

CERTIFICATE OF MAILING  
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

March 26, 2002

Date

Mark B. Wilson

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10112032/MBW.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Mark B. Wilson  
Reg. No. 37,259  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: March 26, 2002

GP 1635 #5

FULBRIGHT & JAWORSKI L.L.P.


A REGISTERED LIMITED LIABILITY PARTNERSHIP

TELEPHONE: 512/474-5201  
FACSIMILE: 512/536-4598

MARK B. WILSON  
PARTNER

INTERNET ADDRESS:  
MBWILSON@FULBRIGHT.COM

DIRECT DIAL: 512/536-3035



500 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701

RECEIVED

APR 03 2002

TECH CENTER 1600/2900

HOUSTON  
WASHINGTON, D.C.  
AUSTIN  
SAN ANTONIO  
DALLAS  
NEW YORK  
LOS ANGELES  
MINNEAPOLIS  
LONDON  
HONG KONG

March 26, 2002

FILE: UTSD:736US

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
March 26, 2002	
Date	Mark B. Wilson

Commissioner for Patents  
Washington, DC 20231

RE: SN 10/023,437 "METHODS AND COMPOSITIONS FOR VACCINATION  
COMPRISING NUCLEIC ACID AND/OR POLYPEPTIDE SEQUENCES OF  
CHLAMYDIA" - Stephen A. Johnston et al. (Client Reference: UTSMC/DAL:736)

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references (A1, C1-C29).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10112032/MBW.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Mark B. Wilson  
Reg. No. 37,259

MBW/cmb

Encl: as noted

7

Form PTO-1449 (modified)

Atty. Docket No.  
UTSD:736US/MBWSerial No.  
10/023,437

List of Patents and Publications for Applicant's

Applicant  
Stephen A. Johnston, *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:  
December 17, 2001Group:  
1635U.S. Patent Documents  
See Page 1Foreign Patent Documents  
See Page 1Other Art  
See Page 1

RECEIVED

APR 03 2002

TECH CENTER 1600/2900

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	5,703,057	12/30/97	Johnston <i>et al.</i>	514	44	4/7/95

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Alberti <i>et al.</i> , "Specific cellular and humoral immune response in Balb/c mice immunised with an expression genomic library of <i>Trypanosoma cruzi</i> ," <i>Vaccine</i> , 16(6):608-612, 1998.
	C2	Babiuk, "Broadening the approaches to developing more effective vaccines," <i>Vaccine</i> , 17:1587-1895, 1999.
	C3	Barry <i>et al.</i> , "Protection against mycoplasma infection using expression-library immunization," <i>Nature</i> , 377:632-635, 1995.
	C4	Brayton <i>et al.</i> , "Expression library immunization to identify protective antigens from <i>Cowdria ruminantium</i> ," <i>Ann. NY Acad. Sci.</i> , 849:369-371, 1998.
	C5	Ellis, "New technologies for making vaccines," <i>Vaccine</i> , 17:1596-1604, 1999.
	C6	Feltquate, <i>et al.</i> , "Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization," <i>J Immunol</i> , 158:2278-2284, 1997.
	C7	Huang, <i>et al.</i> , "IL-12 administered during <i>Chlamydia psittaci</i> lung infection in mice confers immediate and long-term protection and reduces MIP-2 level and neutrophil infiltration in lung tissue," <i>J. Immunol.</i> , 162:2217-2226, 1999.
	C8	Johnston and Barry, "Genetic to genomic vaccination," <i>Vaccine</i> , 15(8):808-809, 1997.
	C9	Kalman <i>et al.</i> , "Comparative genomes of <i>Chlamydia pneumoniae</i> and <i>C. trachomatis</i> ," <i>Nature Genetics</i> , 21:385-389, 1999.

25141202.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.  
UTSD:736US/MBWSerial No.  
10/023,437

List of Patents and Publications for Applicant's

Applicant  
Stephen A. Johnston, *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. Patent Documents  
See Page 1Foreign Patent Documents  
See Page 1Other Art  
See Page 1RECEIVED  
APR 03 2002  
TECH CENTER 1600/2900

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C10	Kaltenbock <i>et al.</i> , "Genetically determined vigorous innate immunity is associated with protection against primary chlamydial lung infection in mice, but with profound disease exacerbation in reinfection," <i>In Chlamydial Infections: Proceedings of the 9th International Symposium on Human Chlamydial Infection</i> , E. A. R. Stephens, ed., 1998.
	C11	Kaltenbock <i>et al.</i> , "Evidence for numerous omp1 alleles of porcine <i>Chlamydia trachomatis</i> and novel chlamydial species obtained by PCR," <i>J. Clin. Microbiol.</i> , 35:1835-1841, 1997.
	C12	Kaltenboeck <i>et al.</i> , "Structures of and allelic diversity and relationships among the major outer membrane protein (ompA) genes of the four chlamydial species," <i>J Bacteriol.</i> , 175(2):487-502, 1993.
	C13	Longbottom <i>et al.</i> , "Identification of a multigene family coding for the 90 kDa proteins of the ovine abortion subtype of <i>Chlamydia psittaci</i> ," <i>FEMS Microbiology Letters</i> , 142:277-281, 1996.
	C14	Longbottom, <i>et al.</i> , "Molecular cloning and characterization of the genes coding for the highly immunogenic cluster of 90-kilodalton envelope proteins from the <i>Chlamydia psittaci</i> subtype that causes abortion in sheep," <i>Infect Immun</i> , 66:1317-1324, 1998.
	C15	Manoutcharian <i>et al.</i> , "Protection against murine cysticercosis using cDNA expression library immunization," <i>Immunol. Lett.</i> , 62:131-136, 1998.
	C16	Meijer <i>et al.</i> "Genomic relatedness of <i>Chlamydia</i> isolates determined by amplified fragment length polymorphism analysis," <i>J. Bacteriology</i> , 181:4469-4475, 1999.
	C17	Morrison, <i>et al.</i> , "Gene knockout mice establish a primary protective role for major histocompatibility complex class II-restricted responses in <i>Chlamydia trachomatis</i> genital tract infection," <i>Infect. Immun.</i> , 63:4661-4668, 1995.
	C18	Piedrafita <i>et al.</i> , "Protective immune response induced by vaccination with an expression genomic library of <i>Leishmania major</i> ," <i>Journal of Immunology</i> , 163:1467-1472, 1998.
	C19	Rottenberg, <i>et al.</i> , "Role of innate and adaptive immunity in the outcome of primary infection with <i>Chlamydia pneumoniae</i> , as analyzed in genetically modified mice," <i>J. Immunol.</i> , 162:2829-2836, 1999.
	C20	Sanford, <i>et al.</i> , "An improved, helium-driven biolistic device," <i>Technique</i> , 3:3-16, 1991.
	C21	Smooker <i>et al.</i> , "Expression library immunization protects mice against a challenge with virulent rodent malaria," <i>Vaccine</i> , 18:2533-2540, 2000.

25141202.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)


Atty. Docket No.  
UTSD:736US/MBWSerial No.  
10/023,437

List of Patents and Publications for Applicant's

Applicant  
Stephen A. Johnston, *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:  
December 17, 2001Group:  
1635U.S. Patent Documents  
See Page 1Foreign Patent Documents  
See Page 1Other Art  
See Page 1

RECEIVED

APR 03 2002

TECH CENTER 1600/2900

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C22	Stephens <i>et al.</i> , "Genome sequence of an obligate intracellular pathogen of humans: <i>Chlamydia trachomatis</i> ," <i>Science</i> , 282:754-759, 1998.
	C23	Sykes and Johnston, "Genetic live vaccines mimic the antigenicity but not pathogenicity of live viruses," <i>DNA Cell. Biol.</i> , 18(7):521-531, 1999.
	C24	Tan, <i>et al.</i> , "Protection of sheep against <i>Chlamydia psittaci</i> infection with a subcellular vaccine containing the major outer membrane protein," <i>Infect Immun</i> , 58:3101-3108, 1990.
	C25	Tang <i>et al.</i> , "Genetic immunization is a simple method for eliciting an immune response," <i>Nature</i> , 356:152-154, 1992.
	C26	Ulmer and Liu, "ELI's coming: expression library and vaccine antigen discovery," <i>Comment Viewpoint</i> .
	C27	Vanrompay <i>et al.</i> , "Protection of turkeys against <i>Chlamydia psittaci</i> challenge by gene gun-based DNA immunizations," <i>Vaccine</i> , 17:2628-2635, 1999.
	C28	Vanrompay <i>et al.</i> , "Protection of turkeys against <i>Chlamydia psittaci</i> challenge by parenteral and mucosal inoculations and the effect of turkey interferon-gamma on genetic immunization," <i>Immunology</i> , 103:106-112, 2001.
	C29	Vanrompay <i>et al.</i> , "Turkeys are protected from infection with <i>Chlamydia psittaci</i> by plasmid DNA vaccination against the major outer membrane protein," <i>Clin. Exp. Immunol.</i> , 118:49-55, 1999.
	C30	Co-pending U.S. Patent Application Serial Number 09/738,269 by Stephen A. Johnston <i>et al.</i> , filed December 15, 2000.

25141202.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)